Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V3-Cervix in Patients With Cervical Cancer
NCT03550755Phase 2Unknown
- Sponsor
- Immunitor Inc.
- Start
- Jul 2018
- Primary completion
- Nov 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of V3-Cervix in Cervical Cancer (CC), sponsored by Immunitor Inc. Primary endpoint: Changes in tumor size and burden compared to baseline. Status: unknown.
02
Drugs
V3-Cervix
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03550755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03550755.